CPI State secretary Gujjula Eswaraiah alleged that Andhra Pradesh's political leaders extract about ₹1,000 crore annually from a fake‑medicine mafia, with half of the state's 60,000 drug stores run by unqualified operators and banned drugs still being sold. The claim underscores systemic corruption, public‑health risks, and the need for stronger regulatory and anti‑corruption measures.
Overview On February 14, 2026 , CPI State secretary Gujjula Eswaraiah alleged that political leaders in Andhra Pradesh are siphoning roughly ₹1,000 crore annually from a fake‑medicine mafia. Speaking at a press conference in Nellore , he highlighted systemic corruption in the pharmaceutical retail sector, the prevalence of unqualified drug‑store operators, and the continued sale of banned drugs under new names. The statements raise serious concerns about public health, governance, and the effectiveness of regulatory mechanisms. Key Developments Alleged Bribe Extraction: Eswaraiah claimed that corrupt political leadership extracts about ₹1,000 crore each year from the pharma mafia. Qualification Gap in Drug Stores: Of the estimated 60,000 drug stores in the state, only 30,000 are run by individuals holding a B. Pharmacy or D. Pharmacy degree; the remaining half operate on mere certificates. Sale of Banned Drugs: Drugs prohibited a decade ago continue to be sold illegally after being re‑branded, posing a direct threat to public health. Important Facts Statistical Snapshot: 60,000 drug stores; 30,000 qualified vs. 30,000 unqualified operators. Proposed Equipment Allocation: Supplying ₹5 lakh worth of medical equipment to each government hospital could curb the influence of the corporate medical mafia. UPSC Relevance This issue intersects multiple sections of the UPSC syllabus. In GS Paper II (Governance, Constitution, Polity) , it touches upon corruption, regulatory failures, and the role of state machinery. GS Paper III (Economics & Development) relates to the economic impact of illicit pharma trade and the financial loss to the exchequer. GS Paper I (Science & Technology, Health) covers public health implications of fake medicines and the need for robust quality‑control mechanisms. Potential question angles include: evaluating the effectiveness of the Drugs and Cosmetics Act, discussing anti‑corruption measures in health‑sector procurement, and analysing the socio‑economic consequences of unregulated pharma markets. Way Forward Policy recommendations include strengthening the enforcement of the Drugs and Cosmetics Act through regular audits of pharmacy licences, mandating digital verification of qualifications, and establishing a transparent, centrally monitored fund for equipping government hospitals. Additionally, a dedicated anti‑mafia task force with powers to trace financial flows could deter the alleged ₹1,000‑crore bribe network. Ensuring affordable, quality healthcare for the common man remains pivotal for both public welfare and the credibility of democratic institutions.